Targets › SLC22A12
2 programs from 2 companies in 5 trials: 2 Phase 3, 2 Phase 2, 1 Phase 4; Metabolic and endocrine, Cardiovascular; next expected readout Jul 2027.
Electroneutral antiporter that translocates urate across the apical membrane of proximal tubular cells in exchange for monovalent organic or inorganic anions. Involved in renal reabsorption of urate and helps maintaining blood levels of uric acid. (UniProt, Q96S37)
Open in Phaseline: the race on SLC22A12, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Crystalys Therapeutics | Dotinurad Solute carrier family 22 member 12 inhibitor | SLC22A12 | Phase 3 | Gout; Tophaceous Gout; Hyperuricemia or Gout | Jul 2027 |
| Jiangsu HengRui Medicine | Shr-4640 (SHR4640) Solute carrier family 22 member 12 inhibitor | SLC22A12 | Phase 2 | Primary Gout and Hyperuricemia | Jul 2027 |
Gout (2) Tophaceous Gout (1) Hyperuricemia or Gout (1) Primary Gout and Hyperuricemia (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.